First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature


Cite item

Full Text

Abstract

Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen. In the article we present a literature review and describe our clinical case of nALCL, ALK-. For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient.

About the authors

N G CHERNOVA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

Email: ngchernova@mail.ru
к.м.н., врач-гематолог отд-ния интенсивной химиотерапии лимфом, тел.: 8(495)612-48-10 (раб.), 8(916)660-27-63 (моб.); ; http://orcid.org/0000-0002-0827-4052 Moscow, Russia

E E ZVONKOV

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

д.м.н., зав. отд-нием; http://orcid.org/0000-0002-2639-7419 Moscow, Russia

D S BADMAZHAPOVA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

аспирант; https://orcid.org/0000-0002-4223-2366 Moscow, Russia

M N SINITSYNA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

н.с.; http://orcid.org/0000-0002-0750-8005 Moscow, Russia

L A GREBENYUK

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

ведущий специалист по молекулярной биологии; http://orcid.org/0000-0003-2117-8775 Moscow, Russia

Y V SIDOROVA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

к.м.н., с.н.с.; http://orcid.org/0000-0003-1936-0084 Moscow, Russia

I E KOSTINA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

к.м.н., зав. отд-нием; https://orcid.org/0000-0003-4683-4118 Moscow, Russia

A M KOVRIGINA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

д.б.н., зав. патологоанатомическим отд-нием; https://orcid.org/0000-0002-1082-8659 Moscow, Russia

T N OBUKHOVA

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

к.м.н., зав. лабораторией; https://orcid.org/0000-0003-1613-652X Moscow, Russia

A B SUDARIKOV

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

д.б.н., зав. лабораторией; https://orcid.org/0000-0001-9463-9187 Moscow, Russia

V G SAVCHENKO

Lymphoma intensive chemotherapy department National Research Center for Hematology, Russian Federation

акад. РАН, проф., генеральный директор; https://orcid.org/0000-0001-8188-5557 Moscow, Russia

References

  1. Swerdlow S.H, Campo E, Harris N.L, Jaffe E.S, Pileri S.A, Stein H, Thiele J, Arber D.A, Hasserjian R.P, Le Beau M.M, Orazi A, Siebert R. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC, 2017: 418-421.
  2. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.International T-Cell Lymphoma Project. J Clin Oncol. 2008 (Sep 1); 26(25): 4124-30. https://doi: 10.1200/JCO.2008.16.4558
  3. Stein H, Foss H.D, Dürkop H, Marafioti T, Delsol G, Pulford K, Pileri S, Falini B. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000 (Dec 1); 96(12):3681-95.
  4. Falini B. Anaplastic large cell lymphoma: pathological, molecular and clinical features. Br J Haematol. 2001( Sep); 114(4):741-60.
  5. Falini B, Pileri S, Zinzani PL, Carbone A, Zagonel V, Wolf-Peeters C, Verhoef G, Menestrina F, Todeschini G, Paulli M, Lazzarino M, Giardini R, Aiello A, Foss HD, Araujo I, Fizzotti M, Pelicci P.G, Flenghi L, Martelli M.F, Santucci A. ALK+ lymphoma: clinico - pathological findings and outcome. Blood. 1999 (Apr 15); 93(8):2697-706.
  6. Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. Монография. М.: Издательство "Медицинское информационное агентство", 2007.
  7. Parrilla Castellar E.R, Jaffe E.S, Said J.W, Swerdlow S.H, Ketterling R.P, Knudson R.A, Sidhu J.S, Hsi E.D, Karikehalli S, Jiang L, Vasmatzis G, Gibson S.E, Ondrejka S, Nicolae A, Grogg K.L, Allmer C, Ristow K.M, Wilson W.H, Macon W.R, Law M.E, Cerhan J.R, Habermann T.M, Ansell S.M, Dogan A, Maurer M.J, Feldman A.L. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014 (Aug 28); 124(9):1473-80. https://doi: 10.1182/blood-2014-04-571091
  8. Khoury J.D, Medeiros L.J, Rassidakis G.Z, Yared M.A, Tsioli P, Leventaki V, Schmitt-Graeff A, Herling M, Amin H.M, Lai R. Differential expression and clinical significance of tyrosine - phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma. Clin Cancer Res. 2003; 9(10 Pt 1): 3692-3699.
  9. Crescenzo R, Abate F, Lasorsa E, Tabbo' F, Gaudiano M, Chiesa N, Di Giacomo F, Spaccarotella E, Barbarossa L, Ercole E, Todaro M, Boi M, Acquaviva A, Ficarra E, Novero D, Rinaldi A, Tousseyn T, Rosenwald A, Kenner L, Cerroni L, Tzankov A, Ponzoni M, Paulli M, Weisenburger D, Chan W.C, Iqbal J, Piris M.A, Zamo' A, Ciardullo C, Rossi D, Gaidano G, Pileri S, Tiacci E, Falini B, Shultz L.D, Mevellec L, Vialard J.E., Piva R, Bertoni F, Rabadan R, Inghirami G. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015; 27:516-532. https://doi: 10.1016/j.ccell.2015.03.006
  10. Atsaves V, Tsesmetzis N, Chioureas D, Kis L, Leventaki V, Drakos E, Panaretakis T, Grander D, Medeiros L.J, Young K.H, Rassidakis G.Z. PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large - cell lymphoma. Leukemia. 2017( Jul); 31(7):1633-1637. https://doi: 10.1038/leu. 2017.103
  11. Виноградова Ю.Е., Луценко И.Н., Капланская И.Б., Воробьев И.А., Самойлова Р.С., Горгидзе Л.А., Рыжикова Н.В., Валиев Т.Т., Гилязитдинова Е.А., Джулакян У.Л., Егорова Е.К., Звонков Е.Е., Красильникова Б.Б., Магомедова А.У., Марголин О.В., Марьин Д.С., Кременецкая А.М., Кравченко С.К., Воробьев А.И. Эффективность терапии различных вариантов анаплазированных Т-крупноклеточных лимфом. Терапевтический архив. 2008; 80(7): 33-37.
  12. Savage K.J, Harris N.L, Vose J.M, Ullrich F, Jaffe E.S, Connors J.M, Rimsza L, Pileri S.A, Chhanabhai M, Gascoyne R.D, Armitage J.O, Weisenburger D.D. International Peripheral T-Cell Lymphoma Project. ALK- anaplastic large - cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. 2008 (Jun 15); 111(12):5496-504. https://doi: 10.1182/blood-2008-01-134270
  13. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho A.D, Metzner B, Peter N, Loeffler M, Rosenwald A, Pfreundschuh M. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010 (Nov 4); 116(18): 3418-25. https://doi: 10.1182/blood-2010-02-270785
  14. d'Amore F, Relander T, Lauritzsen G.F, Jantunen E, Hagberg H, Anderson H, Holte H, Österborg A, Merup M, Brown P, Kuittinen O, Erlanson M, Østenstad B, Fagerli UM, Gadeberg OV, Sundström C, Delabie J, Ralfkiaer E, Vornanen M, Toldbod H.E. Up - front autologous stem - cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol. 2012 (Sep 1); 30(25):3093-9. https://doi: 10.1200/JCO. 2011.40.2719
  15. Mak V, Hamm J, Chhanabhai M, Shenkier T, Klasa R, Sehn L.H, Villa D, Gascoyne R.D, Connors J.M, Savage K.J. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long - term survivors. Clin Oncol. 2013 (Jun 1); 31(16):1970-6. https://doi: 10.1200/JCO.2012.44.7524
  16. Vose J.M, Link B.K, Grossbard M.L, Czuczman M, Grillo-Lopez A, Fisher R.I. Long - term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2005 (Nov); 46(11):1569-73. https://doi: 10.1080/10428190500217312
  17. Younes A, Bartlett N.L, Leonard J.P, Kennedy D.A, Lynch C.M, Sievers E.L, Forero-Torres A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 (Nov 4); 363(19):1812-21. https://doi: 10.1056/NEJMoa1002965
  18. Pro B, Advani R, Brice P, Bartlett N.L, Rosenblatt J.D, Illidge T, Matous J, Ramchandren R, Fanale M, Connors J.M., Fenton K, Huebner D, Pinelli J.M, Kennedy D.A, Shustov A. Five - year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017 (Dec 21); 130(25): 2709-2717. https://doi: 10.1182/blood-2017-05-780049
  19. Bartlett N.L, Chen R, Fanale M.A, Brice P, Gopal A, Smith S.E, Advani R, Matous J.V, Ramchandren R, Rosenblatt J.D, Huebner D, Levine P, Grove L, Forero-Torres A. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 2014 (Mar 19); 7:24. https://doi: 10.1186/1756-8722-7-24
  20. Abid M.B, Wang S, Loi H.Y, Poon L.M. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol. 2016 (Oct); 95(10):1725-6. https://doi: 10.1007/s00277-016-2746-3
  21. Al-Rohil R.N, Torres-Cabala C.A, Patel A, Tetzlaff M.T, Ivan D, Nagarajan P, Curry J.L, Miranda R.N, Duvic M, Prieto V.G, Aung P.P. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding. J Cutan Pathol. 2016 (Dec); 43(12):1161-1166. https://doi: 10.1111/cup.12797
  22. Fanale M.A, Horwitz S.M, Forero-Torres A, Bartlett N.L, Advani R.H, Pro B, Chen R.W, Davies A, Illidge T, Huebner D, Kennedy D.A, Shustov A.R. Brentuximab vedotin in the front - line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 (Oct 1); 32(28): 3137-43. https://doi: 10.1200/JCO. 2013.54.2456
  23. A Comparison of Brentuximab Vedotin and CHP with Standard - of - care CHOP in the Treatment of Patients with CD30-positive Mature T-cell Lymphomas (ECHELON-2). ClinicalTrials.gov Identifier: NCT01777152.
  24. Программное лечение заболеваний системы крови: сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. Под ред. В.Г. Савченко. М.: Издательство “Практика”, 2012.
  25. Горенкова Л.Г., Кравченко С.К. Результаты и перспективы лечения анапластической крупноклеточной лимфомы у взрослых пациентов. Гематология и трансфузиология. 2016; 61: 14.

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies